Ordaos Bio: Funding, Investors & Team (Sep 2026)
Ordaōs is a human-enabled, machine-driven drug design company. Through partnership with industry and academia, the dedicated Ordaōs team leverages proprietary generative perception systems and reinforcement learning to create bespoke mini-proteins that help pharma and biotechs around the world deliver safer and more effective life-saving treatments in a fraction of the time of traditional discovery methods. Ordaōs does this by creating billions of proteins and evaluating their properties in silico, to reliably and repeatedly deliver de novo mini-proteins that achieve the requirements drug hunters only dream of. Ordaōs then proves its consistency and unparalleled efficacy by rigorously synthesizing and testing top-ranking sequences in vitro. The result is Ordaōs miniPRO™, a class of mini-proteins that threaten to revolutionize the role of proteins in drug discovery. miniPRO™ proteins provide the power and performance of antibodies, but are configurable, more stable, and easier to manufacture. By maximizing drug candidate delivery speed, novelty, and probability of clinical success, Ordaōs can provide the highest client confidence in every investigational new drug (IND) application. What’s more, clients that work with Ordaōs see a return on their investment in weeks, rather than months or years. Most importantly, Ordaōs miniPRO™ proteins help birth novel therapies that reduce patient suffering, improve health, and extend life.
Ordaos Bio has raised $18.8M across 3 funding rounds on record, the most recent an undisclosed round of $3.1M announced in Sep 2024.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Ordaos Bio Company Profile and Key Stats
Latest funding round on record: Sep 2024.
Ordaos Bio Funding Rounds
Ordaos Bio raised $10.7M in an undisclosed round announced in Jun 2022.
2 months later, a Seed of $5.0M was announced in Aug 2022.
2.1 years later, an undisclosed round of $3.1M was announced in Sep 2024.
Ordaos Bio Founders and Leadership Team
Contact details for the Ordaos Bio team: 1 of 1 has an email address on file.
Start 14-day free trial →Ordaos Bio Funding Compared to Other Biotechnology Startups
Ordaos Bio's latest round of $3.1M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Ordaos Bio in Biotechnology and Manhattan
Companies Similar to Ordaos Bio
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Ordaos Bio Funding FAQs
What does Ordaos Bio do?
Ordaōs is a human-enabled, machine-driven drug design company. Through partnership with industry and academia, the dedicated Ordaōs team leverages proprietary generative perception systems and reinforcement learning to create bespoke mini-proteins that help pharma and biotechs around the world deliver safer and more effective life-saving treatments in a fraction of the time of traditional discovery methods. Ordaōs does this by creating billions of proteins and evaluating their properties in silico, to reliably and repeatedly deliver de novo mini-proteins that achieve the requirements drug hunters only dream of. Ordaōs then proves its consistency and unparalleled efficacy by rigorously synthesizing and testing top-ranking sequences in vitro. The result is Ordaōs miniPRO™, a class of mini-proteins that threaten to revolutionize the role of proteins in drug discovery. miniPRO™ proteins provide the power and performance of antibodies, but are configurable, more stable, and easier to manufacture. By maximizing drug candidate delivery speed, novelty, and probability of clinical success, Ordaōs can provide the highest client confidence in every investigational new drug (IND) application. What’s more, clients that work with Ordaōs see a return on their investment in weeks, rather than months or years. Most importantly, Ordaōs miniPRO™ proteins help birth novel therapies that reduce patient suffering, improve health, and extend life.
How much funding has Ordaos Bio raised?
Ordaos Bio has raised $18.8M across 3 rounds on record. The most recent is an undisclosed round of $3.1M announced in Sep 2024.
When did Ordaos Bio last raise funding?
Ordaos Bio's most recent funding round on record is an undisclosed round of $3.1M, announced in Sep 2024.
Who founded Ordaos Bio?
FundedIQ lists David Longo (Founder) at Ordaos Bio.
Where is Ordaos Bio headquartered?
Ordaos Bio is based in Manhattan, New York, United States.
How many employees does Ordaos Bio have?
Ordaos Bio is in the 11-50 employee band.
How does Ordaos Bio's funding compare to other Biotechnology startups?
Ordaos Bio's latest round of $3.1M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Ordaos Bio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Ordaos Bio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.